Clinical trials: Mycobacterial Disease
GATA2 Deficiency
Natural History Study of GATA2 Deficiency and Related Disorders
Background: GATA2 deficiency is a genetic disorder that can cause problems with a person s immune system and other body systems. Some people who have this disorder develop few problems from it.
- Trial name
- NCT01905826
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Seropositivity, Tuberculosis
Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients
A multicenter, randomized, stratified, open-label, phase IV trial among HIV-positive persons (PLHIV) on antiretroviral therapy (ART), or HIV-negative household contacts of patients with rifampicin-sensitive pulmonary tuberculosis…
- Conditions
- HIV Seropositivity, Tuberculosis, Household Contact
- Trial name
- 1 to 3 (NCT05118490)
- Testing
- Daily rifapentine and isoniazid for 4 weeks, Weekly rifapentine and isoniazid for 12 weeks
- Where
- 4 sites in India, Indonesia and 2 more
- Volunteers
- 1,000 people
- Sponsor
- The Aurum Institute NPC
Pulmonary Tuberculosis
Efficacy and Safety of Qinbudan as an Adjunct Therapy for Retreatment Pulmonary Tuberculosis
The purpose of this study is to assess the efficacy and safety of Chinese medicine Qinbudan in Patients Receiving Standard Combination Therapy for Retreatment Pulmonary Tuberculosis.
- Trial name
- NCT02313610
- Testing
- Qinbudan
- Where
- 12 sites in China
- Volunteers
- 253 people
- Sponsor
- Shanghai University of Traditional Chinese Medicine
Pulmonary Tuberculosis
Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
A5409/RAD-TB is an adaptive Phase 2 randomized, controlled, open-label, dose-ranging, platform protocol to evaluate the safety and efficacy of multidrug regimens for the treatment of adults with drug-susceptible pulmonary…
- Trial name
- RAD-TB (NCT06192160)
- Testing
- Isoniazid, Rifampicin, Pyrazinamide
- Where
- 30 sites in Botswana, Brazil and 12 more
- Volunteers
- 315 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Latent Tuberculosis, Diabete Mellitus
Comorbidities and Coinfections in Latent TB
Approximately 2 billion people worldwide are infected with Mycobacterium tuberculosis (TB), with 90% of individuals having latent infection (LTBI).
- Conditions
- Latent Tuberculosis, Diabete Mellitus, Malnutrition, Helminth Infection
- Trial name
- COMBINE-TB (NCT04642755)
- Where
- India
- Volunteers
- 300 people
- Sponsor
- Tuberculosis Research Centre, India
Tuberculosis
Can Screening People Registering With Primary Care Improve the Detection of Tuberculosis?
This randomised controlled trial tests whether screening people registering with general practices cost-effectively increases the detection of tuberculosis. The study objectives are to: 1.
- Trial name
- NCT00214708
- Testing
- Screening for Tuberculosis
- Where
- United Kingdom
- Sponsor
- Barts & The London NHS Trust
Tuberculosis, Tuberculosis, Pulmonary
Feasibility of a Lateral Flow Urine Lipoarabinomannan (LAM) Test for Diagnosis of Tuberculosis
The purpose of this study is to evaluate the accuracy, diagnostic yield, operational performance, and time to diagnosis of a novel lateral-flow urine lipoarabinomannan (LAM) test in detecting tuberculosis in HIV-infected adults.
- Conditions
- Tuberculosis, Tuberculosis, Pulmonary, Tuberculosis, Miliary
- Trial name
- NCT01525134
- Testing
- Alere "Determine" lateral-flow urine lipoarabinomannan assay, Alere "Clearview" ELISA urine LAM assay
- Where
- 2 sites in Uganda
- Volunteers
- 504 people
- Sponsor
- Tuberculosis Clinical Diagnostics Research Consortium
Tuberculosis (TB)
A Confirmatory Trial of Adjunctive NAC to Prevent Post Tuberculosis Lung Disease
The goal of this clinical trial is to evaluate if N-acetylcysteine (NAC) works to prevent post-tuberculosis lung disease (PTLD) in patients with severe pulmonary impairment. It also aims to assess the safety of NAC.
- Trial name
- NAC-PTLD (NCT06909799)
- Testing
- N-Acetyl Cysteine (NAC), Standard TB treatment
- Where
- The Gambia
- Volunteers
- 242 people
- Sponsor
- The Aurum Institute NPC
Tuberculosis
Phase 1 Study of PBTZ169
Open-label prospective non-comparative safety, tolerability and pharmacokinetics ascending dose randomized cohort study of PBTZ169 (capsules 40 mg) in fasted healthy volunteers after single and multiple oral administration
- Trial name
- NCT03036163
- Testing
- PBTZ169 - 40 mg, PBTZ169 - 80 mg, PBTZ169 - 160 mg
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Nearmedic Plus LLC
Tuberculosis, Multidrug-Resistant
Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents With Pulmonary MDR-TB
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (explores what the body does to the drug), and anti-mycobacterial activity of bedaquiline (TMC207) in children and adolescents (0 months to less…
- Trial name
- NCT02354014
- Testing
- Bedaquiline (TMC207), Background Regimen (BR)
- Where
- 11 sites in Mozambique, Philippines and 4 more
- Volunteers
- 60 people
- Sponsor
- Janssen Research & Development, LLC
Tuberculosis, HIV Infections
TB (Tuberculosis) Preventive Therapy for HIV Patients With Access to HAART (Highly Active Antiretroviral Therapy)
The purpose of this study is to determine if implementing a policy of widespread INH (Isoniazid) prophylaxis therapy in HIV-infected patients with access to antiretroviral therapy reduces the incidence of active TB disease in the…
- Trial name
- NCT00107887
- Testing
- INH preventive therapy, TST (tuberculin skin test)
- Where
- Brazil
- Volunteers
- 17,415 people
- Sponsor
- Johns Hopkins University
COPD, Interstitial Pneumonia
Perioperative Risk Factors Related to the Prognosis of Lung Transplantation: A Retrospective Study
This study analyzes patients who underwent lung transplantation at the First Affiliated Hospital of Zhejiang University from 2017 to 2024, focusing on anesthesia's impact on post-op results.
- Conditions
- COPD, Interstitial Pneumonia, Bronchiectasis, Respiratory Failure
- Trial name
- NCT06922916
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Zhejiang University
Rifampicin Resistant Tuberculosis, Pulmonary Tuberculosis
Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BLMZ Chinese Cohort
The goal of this clinical trial is to learn if the all-oral, shorter-course BLMZ regimen can treat Rifampicin-Resistant Tuberculosis (RR-TB) in Chinese participants aged 12 years and older.
- Conditions
- Rifampicin Resistant Tuberculosis, Pulmonary Tuberculosis, Tuberculosis, Drug-resistant Tuberculosis
- Trial name
- INSPIRE-BLMZ (NCT07268664)
- Testing
- BLMZ
- Where
- 3 sites in China
- Volunteers
- 120 people
- Sponsor
- Beijing Chest Hospital
Hansen's Disease
Virgin Coconut Oil Oral Supplementation for Leprosy Patients
To date, there has been no clinical investigation on the effects of virgin coconut oil (VCO) oral supplementation on patients with Hansen's disease (HD) undergoing medical treatment.
- Trial name
- NCT01885611
- Testing
- Multi-Drug Therapy (Novartis Ⓡ), Virgin Coconut Oil
- Where
- Philippines
- Sponsor
- Philippine Dermatological Society
MDR-TB, Immunotherapy
A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB
A Exploratory Study of drug combination (zoledronic acid/interleukin 2) that specifically amplifies Vγ2Vδ2 T cells in combination with anti-tuberculosis chemotherapy for the treatment of MDR-TB.
- Trial name
- NCT05493267
- Testing
- Vγ2Vδ2 T lymphocyte-based immunotherapy, Treatment regimens for MDR-TB
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Tuberculosis
Gene Expression in HIV and Tuberculosis Co-infection
Background: Tuberculosis (TB) infection is particularly deadly when it happens in people who are also infected with the human immunodeficiency virus (HIV).
- Trial name
- NCT01611402
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis
Results of an Interferon-Gamma Release Assay After Treatment for Tuberculosis
New blood tests have become available to detect either latent or active tuberculosis. These tests - which according to the CDC can replace the tuberculin skin test - measure the production of gamma-interferon (a cytokine) by…
- Trial name
- NCT00595907
- Where
- Switzerland
- Volunteers
- 89 people
- Sponsor
- University Hospital, Geneva
Tuberculosis, HIV
Evaluation Of The Performance Of The Nitrate Reductase And Resazurin Titre Assay For The Detection of Mycobacterium Tuberculosis Complex From Sputum In A High Tb and Hiv Setting
The Principle objective of this study is To evaluate the performance of NRA, NRA-p and REMA-p for the detection of M. tuberculosis complex from sputum samples from adult pulmonary TB suspects in a high TB and HIV prevalence…
- Conditions
- Tuberculosis, HIV, AIDS, HIV Infections
- Trial name
- NRA RETA (NCT01053598)
- Where
- Uganda
- Volunteers
- 600 people
- Sponsor
- Epicentre
Inflammatory Rheumatic Diseases
A Study on Changes in IFN-gamma Levels Following Anti-TNF Treatment in Patients Undergoing Serial QuantiFERON-TB Gold In-Tube
The screening for latent tuberculosis infection (LTBI) prior to the onset of anti-tumor necrosis factor therapy, as well as a watchful monitoring during the treatment, is strongly recommended.
- Trial name
- NCT01475409
- Testing
- QuantiFERON-TB Gold In-Tube (QFT-GIT)
- Volunteers
- 119 people
- Sponsor
- University of Roma La Sapienza
Pulmonary Tuberculosis
Short Course Regimen in Low Risk Active Tuberculosis- a Multicenter, Randomized, Active-controlled, Trial
Tuberculosis remains an important global health problem, and the world is currently not on track to end the TB epidemic by 2030.
- Trial name
- NCT06727864
- Testing
- 4-month regimen (2HERZ/2HRE), 6-month (2HERZ/4HRE)
- Where
- 8 sites in Taiwan
- Volunteers
- 270 people
- Sponsor
- Kaohsiung Veterans General Hospital.